Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 550-563

  Alongi, Filippo ^a   De Bari, Berardino ^b   Campostrini, Franco ^c   Arcangeli, Stefano ^d   Matei, Deliu Victor ^e   Lopci, Egesta ^a   Petralia, Giuseppe ^f   Bellomi, Massimo ^f   Chiti, Arturo ^a   Magrini, Stefano Maria ^b   Scorsetti, Marta ^a   Orecchia, Roberto ^f   Jereczek Fossa, Barbara Alicja ^f  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Legnago Hospital   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Brachytherapy; Cryotherapy; EBRT; HIFU; Hormonal therapy; Intraprostatic failure; Prostatectomy; Salvage therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER RECURRENCE; COLOR ULTRASOUND FLOWMETRY; CRYOTHERAPY; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SALVAGE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC PROCEDURE; TRANSRECTAL ULTRASONOGRAPHY; TUMOR RECURRENCE;

BRACHYTHERAPY; CRYOTHERAPY; EBRT; HIFU; HORMONAL THERAPY; INTRAPROSTATIC FAILURE; PROSTATECTOMY; SALVAGE THERAPY;

BRACHYTHERAPY; DIAGNOSTIC IMAGING; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84888303356     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.009     Document Type: Review

References (114)

1. Blanco A.I., Michalski J.M. Dose escalation in locally advanced carcinoma of the prostate. Seminars in Radiation Oncology 2003, 13(April (2)):87-97.
2. Viani G.A., da Silva L.G., Stefano E.J. High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. International Journal of Radiation Oncology, Biology, Physics 2012, 83:e619-e625.
3. Magrini S.M., Bertoni F., Vavassori V., et al. Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998). International Journal of Radiation Oncology 2002, 52(April (5)):1310-1319.
4. Zelefsky M.J., Kollmeier M., Cox B., et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2012, 84(September (1)):125-129.
5. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. International Journal of Radiation Oncology, Biology, Physics 2003, 57:915-928.
6. Neppl-Huber C., Zappa M., Coebergh J.W., et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Annals of Oncology 2012, 23(May (5)):1325-1334.
7. Roach M. The role of PSA in the radiotherapy of prostate cancer. Oncology 1996, 10:1143-1153.
8. Agarwal P.K., Sadetsky N., Konety B.R., Resnick M.I., Carroll P.R. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008, 112:307-314.
9. Rosser C.J., Kuban D.A., Levy L.B., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. Journal of Urology 2002, 168(November (5)):2001-2005.
10. American Society of Therapeutic Radiology and Oncology: Consensus statement: guidelines for PSA following radiation therapy International Journal of Radiation Oncology, Biology, Physics 1997, 37:1035-1041.
11. Roach 3rd M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. International Journal of Radiation Oncology, Biology, Physics 2006, 65:965-974.
12. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. International Journal of Radiation Oncology, Biology, Physics 1997, 38:941-947.
13. Martino P., Scattoni V., Galosi A.B., et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World Journal of Urology 2011, 29:595-605.
14. Pucar D., Sella T., Schoeder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Current Opinion in Urology 2008, 18:87-97.
15. Chan T.W., Kressel H.Y. Prostate and seminal vesicles after irradiation: MR appearance. Journal of Magnetic Resonance Imaging 1991, 1:503-511.
16. Rouviere O., Valette O., Grivolat S., et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor - correlation with biopsy findings. Urology 2004, 63:922-927.
17. Arumainayagam N., Kumaar S., Ahmed H.U., et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU International 2010, 106:991-997.
18. Barentsz J.O., Richenberg J., Clements R., et al. ESUR prostate MR guidelines. 2012. European Radiology 2012, 22(April (4)):746-757.
19. Kahn D., Williams R.D., Haseman M.K., et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. Journal of Clinical Oncology 1998, 16:284-289.
20. Sodee D.B., Malguria N., Faulhaber P., et al. Multicenter ProstaScint imaging findings in 2,154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000, 56:988-993.
21. Krause B.J., Souvatzoglou M., Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urologic Oncology 2011, (March). [Epub ahead of print].
22. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. Journal of Nuclear Medicine 2011, 52:81-89.
23. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer and Prostatic Diseases 2006, 9:230-234.
24. Castellucci P., Fuccio C., Nanni C., et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. Journal of Nuclear Medicine 2009, 50:1394-1400.
25. Breeuwsma A.J., Pruim J., Jongen M.M., et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2005, 32:668-673.
26. Hara T., Bansal A., DeGrado T.R. Effect of hypoxia on the uptake of [methyl-3H] choline, [1-14C] acetate and [18F] FDG in cultured prostate cancer cells. Nuclear Medicine and Biology 2006, 33:977-984.
27. Breeuwsma A.J., Pruim J., van den Bergh A.C., et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. International Journal of Radiation Oncology, Biology, Physics 2010, 77:160-164.
28. Rinnab L., Mottaghy F.M., Blumstein N.M., et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU International 2007, 100:786-793.
29. Souvatzoglou M., Krause B.J., Puerschel A., et al. Influence of 11C-choline PET/CT on the treatment planning for savage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiotherapy and Oncology 2011, 99:193-200.
30. Würschmidt F., Petersen C., Wahl A., et al. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiation Oncology 2011, 6:44.
31. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration resistant prostate cancer. European Urology 2011, 59:572-583.
32. NICE clinical guideline 58 - Prostate cancer 15 2013, Available at http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.pdf.
33. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page4%23Reference4.21.
34. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. Journal of Clinical Oncology 2002, 20:4567-4573.
35. Shipley W.U., Desilvio M., Pilepich M.V., et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10. International Journal of Radiation Oncology, Biology, Physics 2006, 64:1162-1167.
36. Tenenholz T.C., Shields C., Ramesh V.R., et al. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urologic Oncology 2007, 25:101-109.
37. Souhami L., Bae K., Pilepich M., et al. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. International Journal of Radiation Oncology, Biology, Physics 2010, 78:1301-1306.
38. Pinover W.H., Horwitz E.M., Hanlon A.L., Uzzo R.G., Hanks G.E. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003, 97(4):1127-1133.
39. Mydin A.R., Dunne M.T., Finn A., Armstrong J.G. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy: a secondary analysis of Irish Clinical Oncology Research Group 97-01. International Journal of Radiation Oncology, Biology, Physics 2013, 85(January (1)):101-108.
40. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology 2006, 24(August (24)):3979-3983.
41. Keating N.L., O'Malley O.J., Smith M.R. Diabetes and cardiovascular disease during ADT therapy for prostate cancer. Journal of Clinical Oncology 2006 Sep 20, 24(27):4448-4456.
42. Sciarra A., Abrahamsson P.A., Brausi M., et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. European Urology 2013, (April). doi:pii: S0302-2838(13)00383-7. 10.1016/j.eururo.2013.04.020.
43. Crook J.M., O'Callaghan C.J., Duncan G., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine 2012, 367(September (10)):895-903.
44. Pontes J.E., Montie J., Klein E., Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer 1993, 71:976-980.
45. Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. Journal of Urology 1992, 147:894-899.
46. Rocco B., Cozzi G., Spinelli M.G., et al. Current status of salvage Robot assisted laparoscopic prostatectomy for radiorecurrent prostate cancer. Current Urology Reports 2012, 13:195-201.
47. Boris R.S., Bhandari A., Krane L.S., Eun D., Kaul S., Peabody J.O. Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes. BJU International 2009, 103:952-956.
48. Eandi J.A., Link B.A., Nelson R.A., et al. Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. Journal of Urology 2010, 183:133-137.
49. Ahlering T.E., Lieskovsky G., Skinner D.G. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. Journal of Urology 1992, 147:900-902.
50. Lerner S.E., Blute M.L., Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. Journal of Urology 1995, 154:1103-1109.
51. Garzotto M., Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. Journal of Urology 1998, 159:950-954. discussion 954-5.
52. Amling C.L., Lerner S.E., Martin S.K., Slezak J.M., Blute M.L., Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. Journal of Urology 1999, 161:857-862. discussion 862-3.
53. Stephenson A.J., Scardino P.T., Bianco F.J., et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. Journal of Urology 2004, 172(December (6 Pt1)):2239-2243.
54. Bianco F.J., Scardino P.T., Stephenson A.J., Diblasio C.J., Fearn P.A., Eastham J.A. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2005, 62:448-453.
55. Ward J.F., Sebo T.J., Blute M.L., Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. Journal of Urology 2005, 173:1156-1160.
56. Darras J., Joniau S., Van Poppel H. Salvage radical prostatectomy for radiorecurrent prostate cancer: indications and results. European Journal of Surgical Oncology 2006, 32:964-969.
57. Sanderson K.M., Penson D.F., Cai J., et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. Journal of Urology 2006, 176:2025-2031. discussion 2031-2.
58. Paparel P., Cronin A.M., Savage C., Scardino P.T., Eastham J.A. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. European Urology 2009, 55(2):404-411.
59. Chade D.C., Shariat S.F., Cronin A.M., et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. European Urology 2011, 60:205-210.
60. Rigatti P., Suardi N., Briganti A., et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11c]choline positron emission tomography/computed tomography. European Urology 2011, 60:935-943.
61. Crook J., Perry G., Robertson S., Esche B. Radiotherapy for localized prostate cancer: assessment of results by systematic biopsy and PSA. Canadian Journal of Urology 1996, 3(March (1)):195-201.
62. Winter A., Uphoff J., Henke R.P., Wawroschek F. First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urologia Internationalis 2010, 84:418-423.
63. Heidenreich A., Ohlmann C., Ozgur E., Engelmann U. Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy. Urologe 2006, 45:474-481.
64. Strope S.A., Coelho M., Wood D.P., Hollenbeck B.K. Robot-assisted salvage prostatectomy: evaluation of initial patient-reported outcomes. Journal of Endourology 2010, 24:425-427.
65. Link P., Freiha F.S. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 1991, 37:189-192.
66. Pisters L.L., von Eschenbach A.C., Scott S.M., et al. The efficacy and complications of salvage cryotherapy of the prostate. Journal of Urology 1997, 157:921.
67. Cohen J.K., Miller R.J., Ahmed S., et al. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008, 71:515-518.
68. Chin J.L., Pautler S.E., Mouraviev V., et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. Journal of Urology 2001, 165(6 Pt 1):1937. discussion 1941.
69. Bahn D.K., Lee F., Silverman P., et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clinical Prostate Cancer 2003, 2:111.
70. Williams A.K., Martinez C.H., Lu C., Ng C.K., Pautler S.E., Chin J.L. Disease free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. European Urology 2011, 60:405-410.
71. Cheetham P., Truesdale M., Chaudhury S., Wenske S., Hruby G.W., Katz A. Long-term cancer-specific and overall survival for men followed more than 10 years after primary and salvage cryoablation of the prostate. Journal of Endourology 2010, 24:1123-1129.
72. Clarke H.S., Eskridge M.R., El-Zawahry A.M., Keane T.E. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Canadian Journal of Urology 2007, 14(Suppl. 1):24-27.
73. Spiess P.E., Katz A.E., Chin J.L., et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU International 2010, 106:1948.
74. Ismail M., Ahmed S., Kastner C., Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU International 2007, 100:760-764.
75. Izawa J.I., Madsen L.T., Scott S.M., et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. Journal of Clinical Oncology 2002, 20:2664.
76. Saliken J.C., Donnelly B.J., Rewcastle J.C. The evolution and state of modern technology for prostate cryosurgery. Urology 2002, 602(August Suppl. 1):26-33.
77. Anastasiadis A.G., Sachdev R., Salomon L., et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. Journal of Cancer Research and Clinical Oncology 2003, 129:676-682.
78. Robinson J.W., Moritz S., Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics 2002, 54:1063-1068.
79. Asterling S., Greene D.R. Prospective evaluation of sexual function in patients receiving cryosurgery as a primary radical treatment for localized prostate cancer. BJU International 2009, 103:788-792.
80. Rebillard X., Soulié M., Chartier-Kastler E., Davin J.-L., Mignard J.-P., Coulange C. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU International 2008, 101:1205-1213.
81. Gelet A., Chapelon J.Y., Bouvier R., et al. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. European Urology 2001, 40:124-129.
82. Murat F.J., Poissonnier L., Rabilloud M., et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. European Urology 2009, 55(March (3)):640-647.
83. Gelet A., Chapelon J.Y., Poissonnier L., et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004, 63:625-629.
84. Crouzet S., Murat F.J., Pommier P., et al. Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensityfocused ultrasound improves oncologic outcomes. Radiotherapy and Oncology 2012, 105(November (2)):198-202.
85. National Collaborating Centre for Cancer CG58 Prostate cancer: evidence review 2008, Available at: http://www.nice.org.uk/nicemedia/pdf/CG58EvidenceReview.
86. National Institute for Health and Clinical Excellence Interventional procedures overview of high-intensity focused ultrasound for prostate cancer 2004, Available at: http://www.nice.org. uk/pdf/ip/IP230overview.
87. Zacharakis E., Ahmed H.U., Ishaq A., et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU International 2008, 102(September (7)):786-792.
88. Ahmed H.U., Ishaq A., Zacharakis E., et al. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU International 2009, 103(February (3)):321-323.
89. Murat F.-J., Poissonnier L., Pricaz E., et al. Prognostic factors for salvage HIFU success after external beam radiation failure (EBRT) failure [abstract]. European Urology Supplements 2008, 7:119.
90. Murat F.-J., Poissonnier L., Rabilloud M., et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. European Urology 2009, 55:640-647.
91. Chen A.M., Philips T.L., Lee N.Y. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how and how much?. International Journal of Radiation Oncology, Biology, Physics 2011, 81:1211-1219.
92. Muller A.C., Eckert F., Heinrich V., Bamberg M., Brucker S., Hehr T. Re-surgery and chest wall re-irradiation for recurrent breast cancer: a second curative approach. BMC Cancer 2011 May 25, 11:197. 10.1186/1471-2407-11-197.
93. Jereczek-Fossa B.A., Kowalczyk A., D'Onofrio A., et al. Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients. Strahlentherapie und Onkologie 2008, 184:36-40.
94. Alongi F., Di Muzio N. Image-guided radiation therapy: a new era for the radiation oncologist?. International Journal of Clinical Oncology 2009, 14(December (6)):568-569.
95. Thariat J., Li G., Angellier G., et al. Current indications and ongoing clinical trials with CyberKnife stereotactic radiotherapy in France in 2009. Bulletin du Cancer 2009, 96:853-864. (article in French).
96. Solberg T.D., Balter J.M., Benedict S.H., et al. Quality and Safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. PRO - Practical Radiation Oncology 2012, 2:2-9.
97. Jereczek-Fossa B.A., Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiotherapy and Oncology 2007, 84:197-215.
98. Vavassori A., Jereczek-Fossa B.A., Beltramo G., et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 2010, 96:71-75.
99. Jereczek-Fossa B.A., Beltramo G., Fariselli L., et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2012, 82:889-897.
100. Ricchetti F., Barra S., Agostinelli S., Vagge S., Marcenaro M., Corvò R. Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. Tumori 2011, 97:492-497.
101. Wang H., Vees H., Miralbell R., et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiotherapy and Oncology 2009, 93:220-225.
102. Pucar D., Hricak H., Shukla-Dave A., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. International Journal of Radiation Oncology, Biology, Physics 2007, 69:62-69.
103. 125Iodine reimplantation for locally progressive prostatic carcinoma. Journal of Urology 1990, 144:704-706.
104. 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate 1993, 23:283-290.
105. Nguyen P.L., Chen M.H., D'Amico A.V., et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007, 110(October (7)):1485-1492.
106. Koutrouvelis P., Hendricks F., Lailas N., et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technology in Cancer Research & Treatment 2003, 2:339-344.
107. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999, 54(November (5)):880-883.
108. Wong W.W., Buskirk S.J., Schild S.E., Prussak K.A., Davis B.J. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. Journal of Urology 2006, 176(November (5)):2020-2024.
109. Moman M.R., van der Poel H.G., Battermann J.J., Moerland M.A., van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 2010, 9(April-June (2)):119-125.
110. Burri R.J., Stone N.N., Unger P., Stock R.G. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2010, 77(August (5)):1338-1344.
111. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2-10.
112. Hsu C.C., Hsu H., Pickett B., et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2012, (June). [Epub ahead of print].
113. Jo Y., Fujii T., Hara R., et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results. BJU International 2012, 109(March (6)):835-839.
114. Lee B., Shinohara K., Weinberg V., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. International Journal of Radiation Oncology, Biology, Physics 2007, 67:1106-1112.